Clinical Trials
10 trialsNCT03362177 2026-02-11
RECITE
Amgen
Phase 3 Completed
NCT04671901 2025-05-28
A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT04478123 2024-02-14
Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00299182 2021-09-21
Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01676961 2018-10-15
Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy
NYU Langone Health
Phase 2 Terminated
NCT01444417 2017-02-09
Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
Amgen
Phase 3 Completed
NCT00515203 2014-07-25
Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects
Amgen
Phase 1/2 Completed
NCT00147225 2014-05-08
AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00413283 2013-10-24
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
Amgen
Phase 2 Completed
NCT00283439 2011-06-20
A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma
Amgen
Phase 1/2 Completed